Previous Article | Next Article 
Journal of Virology, July 1999, p. 6188-6190, Vol. 73, No. 7
Division of Molecular Genetics,
Received 20 January 1999/Accepted 31 March 1999
Studies of virus neutralization by antibody are a prerequisite for
development of a prophylactic vaccine strategy against human
papillomaviruses (HPVs). Using HPV16 and -6 pseudovirions capable of
inducing Human papillomaviruses (HPVs), which
have been classified into more than 70 genotypes, cause a variety of
proliferating epithelial lesions, including skin and cervical cancers.
HPVs are usually grouped on the basis of the pathogenicity and target
tissue. Among HPVs associated with anogenital diseases, high-risk HPV16
is predominantly found in cervical cancer and low-risk HPV6 is found in
benign condylomata (6, 13).
An icosahedral HPV capsid with a diameter of 55 nm consists of 72 pentameric capsomeres composed of structural proteins L1 and L2 with an
estimated molar ratio of 30 to 1. Both type-specific and cross-reactive
antibodies binding to the capsid proteins are detectable in sera from
patients positive for HPV DNAs (13). Neutralizing activities
of anti-L1 antibodies have been studied by using infectious HPV
pseudovirions and surrogate cell culture systems to monitor the
pseudovirus infection (5, 9, 10). So far, anti-L1 antibodies
against HPV6, -11, -16, -18, and -33 have been shown to have a
type-specific neutralizing activity. In this study, we examined the
neutralizing activity of mouse anti-HPV16 L2 monoclonal antibodies
(MAbs) that recognize surface epitopes (4), by using
infectious HPV16 and -6 pseudovirions generated by in vitro packaging
(5).
Eleven anti-HPV16 L2 MAbs used in this study had been obtained in our
previous study (4) by immunization of BALB/c mice with HPV16
L1/L2 capsids (particles self-assembled in insect Sf9 cells expressing
L1 and L2). These MAbs recognize linear surface epitopes of the L1/L2
capsids. Epitopes for 7 of 11 MAbs have been localized within a region
of amino acids (aa) 69 to 81 in HPV16 L2 (the entire L2 protein is
composed of 473 aa residues), but the epitopes for the remaining 4 have
not been determined. Besides the previously used synthetic peptide with
an HPV16 L2 sequence of aa 69 to 81 (P-69/81), two peptides with aa 95 to 107 (P-95/107) and aa 108 to 120 (P-108/120) were used for the assay
of MAbs binding to these peptides (Table
1). The amino acid sequences of the three
peptides are conserved among genital HPVs.
Binding of MAbs to L1/L2 capsids or peptides was measured by
enzyme-linked immunosorbent assay (ELISA), for which capsids in
phosphate-buffered saline (PBS [pH 7.0]) or bovine serum albumin (BSA)-conjugated peptides (synthesized and conjugated by Sawady Technology, Tokyo, Japan) in carbonate buffer (pH 9.6) were fixed in
the wells of an ELISA plate (Dynatech Laboratories, Chantilly, Va.).
The capsids or the three peptides fixed in the plates were used as
antigens after being blocked with 0.2% gelatin in PBS. Diluted ascites
fluid (300 µl/well) containing MAb was added to the wells and
incubated for 1 h at room temperature. Horseradish peroxidase-conjugated, goat anti-mouse immunoglobulin (Ig; Dako Corp.,
Carpinteria, Calif.) (1:2,000 in 1% BSA in PBS) was used as a
secondary antibody. A mixture of 0.01% H2O2
and o-phenylenediamine (2 mg/ml) in 0.1 M citrate buffer (pH
4.7) was added to the wells, and the A450 was
measured. Specific absorbency was calculated by subtracting the
absorbency of mock wells covered with gelatin or BSA.
As shown in Table 1, two MAbs, no. 5 and 13, were found to bind to
P-108/120, whereas seven MAbs, no. 2, 4, 6, 7, 9, 10, and 17, in
agreement with the previous results, bound to P-69/81. Two MAbs, no. 11 and 12, bound to none of the three peptides. The data show that the
epitopes for MAb5 and -13 are in the region of aa 108 to 120.
For the assay of the neutralizing activity, MAb5 (IgG2a), MAb13 (IgG3),
and MAb6 (IgG2a) were selected from those listed in Table 1. MAb5 and
MAb13 bound to the epitope(s) within aa 108 to 120, and MAb6 recognized
an epitope within aa 69 to 81. For comparison, anti-HPV6 L1 and
anti-HPV16 L1 antisera were tested for neutralizing activity. These
antisera were obtained from BALB/c mice injected with purified HPV6 and
HPV16 L1 capsids (particles self-assembled in insect Sf9 cells
expressing L1 alone [7]) without adjuvant,
respectively. For each type, a pool of sera from 10 mice was used.
Neutralizing activity was tested against that of in vitro-reassembled
HPV pseudovirions containing an expression plasmid for Table 2 summarizes the results of assays
for binding activity to the L1/L2 capsids and neutralizing activity of
the antisera and MAbs. As shown previously (5, 9, 10), the
binding and neutralizing activities of anti-L1 antisera were type
specific. The binding and neutralizing activities of MAb6 were also
type specific. In contrast, MAb5 and MAb13 were found to inhibit
pseudoinfections with both HPV16 and -6, strongly suggesting that the
two HPVs have a common L2 neutralization epitope.
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Common Neutralization Epitope in Minor Capsid
Protein L2 of Human Papillomavirus Types 16 and 6
ABSTRACT
Top
Abstract
Text
References
-galactosidase in infected monkey COS-1 cells, we examined
the neutralizing activity of mouse monoclonal antibodies (MAbs) that
recognize surface epitopes in HPV16 minor capsid protein L2. Two MAbs
binding to a synthetic peptide with the HPV16 L2 sequence of amino
acids (aa) 108 to 120 were found to inhibit pseudoinfections with HPV16
as well as HPV6. Antisera raised by immunizing BALB/c mice with the
synthetic peptide had a cross-neutralizing activity similar to that of
the MAb. The data indicate that HPV16 and -6 have a common
cross-neutralization epitope (located within aa 108 to 120 of L2 in
HPV16), suggesting that this epitope may be shared by other genital HPVs.
TEXT
Top
Abstract
Text
References
TABLE 1.
Binding of MAbs to synthetic peptides
-galactosidase. HPV16 pseudovirions were produced and purified as
described previously (5), and HPV6 pseudovirions were
prepared similarly. The pseudovirions at 50 infectious units in 0.1 ml of PBS (pH 6.8) were mixed with 0.1 ml of serial dilutions of the
ascites fluid containing MAb or antisera in PBS (pH 6.8), incubated at
4°C for 1 h, and then mixed with COS-1 cells (4 × 105), which had been dispersed with PBS containing EDTA
(2.5 mM) and washed with Dulbecco's modified Eagle's medium before
mixing, in 0.3 ml of PBS containing BSA (0.01%) for 2 h at 4°C
with constant agitation. The cells were seeded into six-well plates,
grown for 36 h, and fixed with glutaraldehyde. Cells expressing
-galactosidase were stained with X-Gal
(5-bromo-4-chloro-3-indolyl--D-galactopyranoside) as a
substrate (In Situ -Galactosidase Staining Kit; Promega Corp.). The
number of blue cells was counted, and the neutralizing activity was
expressed as a reciprocal of the maximum dilution of serum or ascites
fluid that reduced the number of blue cells to half of that in the
sample treated with PBS containing BSA.
TABLE 2.
Neutralization of pseudoinfection
To further confirm the presence of a type-common neutralization epitope, mouse antisera were raised by immunizing BALB/c mice with the BSA-conjugated peptides P-1/12 and P-108/120, representing HPV16 L2 sequences of aa 1 to 12 and 108 to 120, respectively. Fifty micrograms of the antigen mixed with Freund's complete adjuvant was used for each mouse for the first intracutaneous injection, which was followed by three intraperitoneal injections of the antigen mixed with Freund's incomplete adjuvant at intervals of 2 weeks. For each peptide, sera were collected and pooled from 10 mice at 2 weeks after the final immunization.
Table 2 includes neutralization data with the antisera against the synthetic peptides. Like MAb5 and -13, the anti-P-108/120 sera bound to pseudovirions of both HPV16 and -6 and inhibited pseudoinfections with both HPVs. Thus, the data clearly show that the neutralization epitope common to HPV6 and -16 is in the L2 region of aa 108 to 120 in HPV16.
The L2 region of aa 108 to 120, containing the cross-neutralization epitope for MAb5 and -13, is considered to be on the surface of virions, because the MAbs bind to intact L1/L2 capsids (Table 1). The region close to the N terminus of bovine papillomavirus type 1 (BPV1) L2 appears to be displayed on the surface of the intact virions, as shown by binding of three anti-L2 MAbs recognizing epitopes in an L2 region of aa 61 to 123 (12). Despite the lack of amino acid sequence homology in the N-terminal region, the topographical location of L2 in the virion is probably common to HPVs and BPVs. Furthermore, antibodies against the N-terminal region of BPV L2 (aa 45 to 173 for BPV1 [2, 8], aa 11 to 200 for BPV4 [3], and aa 131 to 151 for BPV4 [1]) have been reported to be involved in neutralization. It is probable, therefore, that binding of anti-L2 antibodies to the surface region of L2 inhibits infection through a common mechanism.
The amino acid sequences of the surface regions corresponding to the HPV16 L2 region of aa 108 to 120 seem to be highly conserved among different HPVs (Fig. 1). The amino acid sequence homology is higher between HPV16 and HPV33/58 than between HPV16 and HPV6. In fact, the guinea pig antiserum binding to an HPV33 L2 sequence of aa 107 to 117 is cross-reactive with the L2 proteins of HPV11, -16, and -18 (11). Although the cross-neutralization between different types remains to be examined, it is likely that this region contains a type-common cross-neutralization epitope among genital HPVs. This epitope may be used as a target for development of a type-common anti-HPV vaccine.
|
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by a grant-in-aid from the Ministry of Health and Welfare for the Second-Term Comprehensive 10-Year Strategy for Cancer Control and by a cancer research grant from the Ministry of Education, Science, and Culture.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Molecular Genetics, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. Phone: (81) 3-5285-1111, ext. 2524. Fax: (81) 3-5285-1166. E-mail: kanda{at}nih.go.jp.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. | Campo, M. S., B. W. O'Neil, G. J. Grindlay, F. Curtis, G. Knowles, and L. M. Chandrachud. 1997. A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease. Virology 234:261-266[Medline]. |
| 2. | Chandrachud, L. M., G. J. Grindlay, G. M. McGarvie, B. W. O'Neil, E. R. Wagner, W. F. H. Jarrett, and M. S. Campo. 1995. Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology 211:204-208[Medline]. |
| 3. |
Gaukroger, J. M.,
L. M. Chandrachud,
B. W. O'Neil,
G. J. Grindlay,
G. Knowles, and M. S. Campo.
1996.
Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies.
J. Gen. Virol.
77:1577-1583 |
| 4. | Kawana, K., K. Matsumoto, H. Yoshikawa, Y. Taketani, T. Kawana, K. Yoshiike, and T. Kanda. 1998. A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2. Virology 245:353-359[Medline]. |
| 5. |
Kawana, K.,
H. Yoshikawa,
Y. Taketani,
K. Yoshiike, and T. Kanda.
1998.
In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids.
J. Virol.
72:10298-10300 |
| 6. | Lorincz, A. T., R. Reid, A. B. Jensen, M. D. Greenberg, A. A. W. Lancaster, and R. J. Kurman. 1991. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet. Gynecol. 79:328-337. |
| 7. | Matsumoto, K., H. Yoshikawa, Y. Taketani, K. Yoshiike, and T. Kanda. 1997. Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid protein among Japanese females. Jpn. J. Cancer Res. 88:369-375[Medline]. |
| 8. |
Roden, R. B. S.,
E. M. Weissinger,
D. W. Henderson,
F. Booy,
R. Kirnbauer,
J. F. Mushinski,
D. R. Lowy, and J. T. Schiller.
1994.
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.
J. Virol.
68:7570-7574 |
| 9. | Roden, R. B. S., H. L. Greenstone, R. Kirnbauer, F. P. Booy, J. Jessie, D. R. Lowy, and J. T. Schiller. 1996. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70:5875-5889[Abstract]. |
| 10. | Unckell, F., R. E. Streeck, and M. Sapp. 1997. Generation and neutralization of pseudovirions of human papillomavirus type 33. J. Virol. 71:2934-2939[Abstract]. |
| 11. |
Volpers, C.,
M. Sapp,
C. A. Komly,
P. Richalet-Secordel, and R. E. Streeck.
1993.
Development of type-specific and cross-reactive serological probes for the minor capsid protein of human papillomavirus type 33.
J. Virol.
67:1927-1935 |
| 12. | Wen, J. L., L. Gissmann, X. Y. Sun, A. Kanjanahaluethai, M. Muller, J. Doorbar, and J. Zhou. 1997. Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions. Virology 227:474-483[Medline]. |
| 13. |
zur Hausen, H.
1996.
Papillomavirus infections a major cause of human cancers.
Biochim. Biophys. Acta
1288(Suppl. 2):F55-F78[Medline].
|
Journal of Virology, July 1999, p. 6188-6190, Vol. 73, No. 7
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Jagu, S., Karanam, B., Gambhira, R., Chivukula, S. V., Chaganti, R. J., Lowy, D. R., Schiller, J. T., Roden, R. B. S.
(2009). Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines. JNCI J Natl Cancer Inst
101: 782-792
[Abstract] [Full Text] -
Gambhira, R., Karanam, B., Jagu, S., Roberts, J. N., Buck, C. B., Bossis, I., Alphs, H., Culp, T., Christensen, N. D., Roden, R. B. S.
(2007). A Protective and Broadly Cross-Neutralizing Epitope of Human Papillomavirus L2. J. Virol.
81: 13927-13931
[Abstract] [Full Text] -
Gambhira, R., Jagu, S., Karanam, B., Gravitt, P. E., Culp, T. D., Christensen, N. D., Roden, R. B. S.
(2007). Protection of Rabbits against Challenge with Rabbit Papillomaviruses by Immunization with the N Terminus of Human Papillomavirus Type 16 Minor Capsid Antigen L2. J. Virol.
81: 11585-11592
[Abstract] [Full Text] -
Laniosz, V., Nguyen, K. C., Meneses, P. I.
(2007). Bovine Papillomavirus Type 1 Infection Is Mediated by SNARE Syntaxin 18. J. Virol.
81: 7435-7448
[Abstract] [Full Text] -
Xu, Y., Wang, Q., Han, Y., Song, G., Xu, X.
(2007). Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles. J Med Microbiol
56: 907-913
[Abstract] [Full Text] -
Holmgren, S. C., Patterson, N. A., Ozbun, M. A., Lambert, P. F.
(2005). The Minor Capsid Protein L2 Contributes to Two Steps in the Human Papillomavirus Type 31 Life Cycle. J. Virol.
79: 3938-3948
[Abstract] [Full Text] -
Devaraj, K., Gillison, M. L., Wu, T.-C.
(2003). DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA. CROBM
14: 345-362
[Abstract] [Full Text] -
Varsani, A., Williamson, A.-L., de Villiers, D., Becker, I., Christensen, N. D., Rybicki, E. P.
(2003). Chimeric Human Papillomavirus Type 16 (HPV-16) L1 Particles Presenting the Common Neutralizing Epitope for the L2 Minor Capsid Protein of HPV-6 and HPV-16. J. Virol.
77: 8386-8393
[Abstract] [Full Text] -
Lowy, D. R., Frazer, I. H.
(2003). Chapter 16: Prophylactic Human Papillomavirus Vaccines. J Natl Cancer Inst Monogr
2003: 111-116
[Abstract] [Full Text] -
Finnen, R. L., Erickson, K. D., Chen, X. S., Garcea, R. L.
(2003). Interactions between Papillomavirus L1 and L2 Capsid Proteins. J. Virol.
77: 4818-4826
[Abstract] [Full Text] -
Yang, R., Yutzy, W. H. IV, Viscidi, R. P., Roden, R. B. S.
(2003). Interaction of L2 with beta -Actin Directs Intracellular Transport of Papillomavirus and Infection. J. Biol. Chem.
278: 12546-12553
[Abstract] [Full Text] -
Yang, R., Day, P. M., Yutzy, W. H. IV, Lin, K.-Y., Hung, C.-F., Roden, R. B. S.
(2003). Cell Surface-Binding Motifs of L2 That Facilitate Papillomavirus Infection. J. Virol.
77: 3531-3541
[Abstract] [Full Text] -
Embers, M. E., Budgeon, L. R., Pickel, M., Christensen, N. D.
(2002). Protective Immunity to Rabbit Oral and Cutaneous Papillomaviruses by Immunization with Short Peptides of L2, the Minor Capsid Protein. J. Virol.
76: 9798-9805
[Abstract] [Full Text] -
Combita, A.-L., Touze, A., Bousarghin, L., Christensen, N. D., Coursaget, P.
(2002). Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human Papillomaviruses. J. Virol.
76: 6480-6486
[Abstract] [Full Text] -
Bousarghin, L., Combita-Rojas, A.-L., Touze, A., El Mehdaoui, S., Sizaret, P.-Y., Bravo, M.-M., Coursaget, P.
(2002). Detection of Neutralizing Antibodies against Human Papillomaviruses (HPV) by Inhibition of Gene Transfer Mediated by HPV Pseudovirions. J. Clin. Microbiol.
40: 926-932
[Abstract] [Full Text] -
Fligge, C., Schafer, F., Selinka, H.-C., Sapp, C., Sapp, M.
(2001). DNA-Induced Structural Changes in the Papillomavirus Capsid. J. Virol.
75: 7727-7731
[Abstract] [Full Text] -
Okun, M. M., Day, P. M., Greenstone, H. L., Booy, F. P., Lowy, D. R., Schiller, J. T., Roden, R. B. S.
(2001). L1 Interaction Domains of Papillomavirus L2 Necessary for Viral Genome Encapsidation. J. Virol.
75: 4332-4342
[Abstract] [Full Text] -
Kawana, Y., Kawana, K., Yoshikawa, H., Taketani, Y., Yoshiike, K., Kanda, T.
(2001). Human Papillomavirus Type 16 Minor Capsid Protein L2 N-Terminal Region Containing a Common Neutralization Epitope Binds to the Cell Surface and Enters the Cytoplasm. J. Virol.
75: 2331-2336
[Abstract] [Full Text] -
Giroglou, T., Florin, L., Schäfer, F., Streeck, R. E., Sapp, M.
(2001). Human Papillomavirus Infection Requires Cell Surface Heparan Sulfate. J. Virol.
75: 1565-1570
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»